We are live on
!
Find out more
BC
Broadwood Capital Portfolio holdings
AUM
$1.42B
1-Year Est. Return
34.72%
This Fund
S&P 500
This Quarter
Est. Return
-15.69%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$508M
AUM Growth
-$79.3M
(-14%)
Cap. Flow
+$44.4M
Cap. Flow
% of AUM
8.74%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
3
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$29.6M |
| 2 |
Lineage Cell Therapeutics
LCTX
|
+$7.8M |
| 3 |
STAAR Surgical
STAA
|
+$4.12M |
| 4 |
CYNO
Cynosure, Inc. Class A
CYNO
|
+$2.82M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.78% |
| 2 | Consumer Staples | 42.55% |
Similar funds
PTC
NI
CBA
KC
EWS
IHG
SCM
PPC
Broadwood Capital's Q3 2015 Portfolio in Review
As of Q3 2015, Broadwood Capital held 7 positions worth $508M, down 14% from $587M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Broadwood Capital deployed $44.4M of net new capital in Q3 2015, opening 1 new position and adding to 3 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 250,000 shares worth $27.3M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 58% a quarter earlier, followed by Consumer Staples.
- Broadwood Capital's largest Q3 2015 buy was iShares Russell 2000 ETF: 250,000 shares worth $27.3M.
- Broadwood Capital added most to Lineage Cell Therapeutics in Q3 2015, an estimated $7.8M increase.
- Broadwood Capital's ten largest holdings make up 100% of its $508M portfolio in Q3 2015.
- Broadwood Capital opened 1 new position and closed 0 in Q3 2015.
- Broadwood Capital's portfolio value fell 14% quarter-over-quarter to $508M.
Based on Broadwood Capital's 13F filing for Q3 2015, filed 16 Nov 2015.